Kurt Von Emster Sells 32,930 Shares of CRISPR THERAPTC (CRSP) Stock

CRISPR THERAPTC (NASDAQ:CRSP) Director Kurt Von Emster sold 32,930 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $17.60, for a total transaction of $579,568.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.81, for a total transaction of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.51, for a total transaction of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.63, for a total transaction of $728,330.56.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.84, for a total transaction of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.56, for a total transaction of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.26, for a total transaction of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.90, for a total transaction of $730,113.80.
  • On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.08, for a total transaction of $1,390,909.80.
  • On Friday, June 23rd, Kurt Von Emster sold 32,368 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.23, for a total transaction of $525,332.64.

Shares of CRISPR THERAPTC (NASDAQ CRSP) opened at 18.74 on Wednesday. The stock’s market capitalization is $749.54 million. The stock has a 50 day moving average of $16.62 and a 200-day moving average of $17.58. CRISPR THERAPTC has a one year low of $11.63 and a one year high of $25.00.

CRISPR THERAPTC (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.06. The company had revenue of $2.70 million for the quarter. Equities analysts forecast that CRISPR THERAPTC will post ($2.46) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Kurt Von Emster Sells 32,930 Shares of CRISPR THERAPTC (CRSP) Stock” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/kurt-von-emster-sells-32930-shares-of-crispr-theraptc-crsp-stock-updated/1309930.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the period. IHT Wealth Management LLC bought a new position in shares of CRISPR THERAPTC during the first quarter worth about $110,000. Monashee Investment Management LLC increased its position in shares of CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the period. Paulson & CO. Inc. bought a new position in shares of CRISPR THERAPTC during the first quarter worth about $1,099,000. Finally, Credit Suisse AG acquired a new position in CRISPR THERAPTC during the first quarter worth approximately $1,742,000. Institutional investors own 24.08% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. SunTrust Banks, Inc. assumed coverage on shares of CRISPR THERAPTC in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a report on Tuesday, July 18th. Finally, Cann assumed coverage on shares of CRISPR THERAPTC in a report on Monday, July 17th. They issued a “market perform” rating on the stock. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. CRISPR THERAPTC presently has a consensus rating of “Buy” and a consensus target price of $21.92.

About CRISPR THERAPTC

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with our FREE daily email newsletter.

 


Latest News

Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies
Boston’s Chris Sale Will Pitch In Each of Three Series With Yankees
Boston’s Chris Sale Will Pitch In Each of Three Series With Yankees
Greg Holland Out For Rockies Following Kitchen Incident
Greg Holland Out For Rockies Following Kitchen Incident
Jon Lester Joins 2,000 Strikeout Club, Hits First Home Run
Jon Lester Joins 2,000 Strikeout Club, Hits First Home Run
Sonny Gray Acquired By Yankees from Athletics
Sonny Gray Acquired By Yankees from Athletics
Adrian Beltre Reaches 3,000 Careers Hits
Adrian Beltre Reaches 3,000 Careers Hits


Leave a Reply

 
© 2006-2017 BBNS.